Cited 0 times in

Implication of Amyloid Precursor-like Protein 2 Expression in Cutaneous Squamous Cell Carcinoma Pathogenesis

Authors
 Xiaodi Huang  ;  Jihye Yang  ;  Haoran Xi  ;  Meilan Zhang  ;  Yeongjoo Oh  ;  Zhehu Jin  ;  Zhenlong Zheng 
Citation
 IN VIVO, Vol.38(1) : 399-408, 2024-01 
Journal Title
IN VIVO
ISSN
 0258-851X 
Issue Date
2024-01
MeSH
Carcinoma, Squamous Cell* / genetics ; Carcinoma, Squamous Cell* / pathology ; Cell Line, Tumor ; Cell Proliferation / genetics ; Histocompatibility Antigens Class I ; Humans ; Oncogenes ; Skin Neoplasms* / genetics ; Skin Neoplasms* / pathology
Keywords
APLP2 ; CSCC ; MHC-I ; immune escape ; pathogenesis
Abstract
Background/aim: Regulatory functions of amyloid precursor-like protein 2 (APLP2) expression in intracellular trafficking of major histocompatibility complex class I (MHC-I) and biological behavior of tumor cells have been reported in various types of malignancies but not in cutaneous squamous cell carcinoma (CSCC). This study aimed to investigate the role of APLP2 expression in the pathogenesis of CSCC.

Patients and methods: The expression of APLP2 and a key modulator of cancer immune escape, MHC-I, were determined in CSCC tissue samples obtained from 141 patients using immunohistochemistry. The regulatory effects of APLP2 expression on the biological behavior and surface expression of MHC-I in CSCC cells were investigated by trypan blue assay, Matrigel invasion assay, and in vivo xenograft analysis.

Results: APLP2 immunoreactivity was high in 73 (51.8%) tissue samples from patients with CSCC and was significantly related to subcutaneous fat invasion and poor prognosis in our cohort. Moreover, proliferation of and invasion by CSCC cells were significantly reduced after APLP2 knockdown in CSCC cells both in vitro and in vivo. A significant association was found between APLP2 and membrane MHC-I expression in patients with CSCC. In vivo xenograft analysis showed that APLP2 knockdown increased membrane MHC-I expression in CSCC cells.

Conclusion: APLP2 not only acts as an oncogene in CSCC progression but also as a possible modulator of cancer immune escape by influencing MHC-I expression on the cell surface. APLP2 may serve as a novel molecular biomarker and therapeutic target for patients with CSCC.
Files in This Item:
T992025091.pdf Download
DOI
10.21873/invivo.13452
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
2. College of Dentistry (치과대학) > Dept. of Oral Pathology (구강병리학교실) > 1. Journal Papers
Yonsei Authors
Yang, Ji Hye(양지혜)
Oh, Yeongjoo(오영주) ORCID logo https://orcid.org/0000-0003-4973-9335
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/204182
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links